These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22951445)

  • 1. Innate inflammation in Parkinson's disease.
    Perry VH
    Cold Spring Harb Perspect Med; 2012 Sep; 2(9):a009373. PubMed ID: 22951445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.
    Mirza B; Hadberg H; Thomsen P; Moos T
    Neuroscience; 2000; 95(2):425-32. PubMed ID: 10658622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and adaptive immunity in Parkinson's disease.
    Mosley RL; Hutter-Saunders JA; Stone DK; Gendelman HE
    Cold Spring Harb Perspect Med; 2012 Jan; 2(1):a009381. PubMed ID: 22315722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Gallups NJ; Standaert DG; Harms AS
    Brain; 2021 Aug; 144(7):2047-2059. PubMed ID: 33704423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of innate immunity and inflammation in Parkinson´s disease.
    Öberg M; Fabrik I; Fabrikova D; Zehetner N; Härtlova A
    Scand J Immunol; 2021 May; 93(5):e13022. PubMed ID: 33471378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease.
    Lee H; James WS; Cowley SA
    Biochem Soc Trans; 2017 Feb; 45(1):131-139. PubMed ID: 28202666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-autonomous cell death in Parkinson's disease.
    Dawson TM
    Lancet Neurol; 2008 Jun; 7(6):474-5. PubMed ID: 18485311
    [No Abstract]   [Full Text] [Related]  

  • 8. Activated immune cells in Parkinson's disease.
    Cao JJ; Li KS; Shen YQ
    J Neuroimmune Pharmacol; 2011 Sep; 6(3):323-9. PubMed ID: 21553347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of innate and adaptive immunity in Parkinson's disease.
    Kannarkat GT; Boss JM; Tansey MG
    J Parkinsons Dis; 2013; 3(4):493-514. PubMed ID: 24275605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate and adaptive immune responses in Parkinson's disease.
    Schonhoff AM; Williams GP; Wallen ZD; Standaert DG; Harms AS
    Prog Brain Res; 2020; 252():169-216. PubMed ID: 32247364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
    Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
    Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease.
    Koprich JB; Reske-Nielsen C; Mithal P; Isacson O
    J Neuroinflammation; 2008 Feb; 5():8. PubMed ID: 18304357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease.
    Kim YS; Joh TH
    Exp Mol Med; 2006 Aug; 38(4):333-47. PubMed ID: 16953112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
    Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
    Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inflammatory review of Parkinson's disease.
    Orr CF; Rowe DB; Halliday GM
    Prog Neurobiol; 2002 Dec; 68(5):325-40. PubMed ID: 12531233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease.
    Panaro MA; Cianciulli A
    Curr Pharm Des; 2012; 18(2):200-8. PubMed ID: 22229581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.
    De Lella Ezcurra AL; Chertoff M; Ferrari C; Graciarena M; Pitossi F
    Neurobiol Dis; 2010 Mar; 37(3):630-40. PubMed ID: 19969084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periphery and brain, innate and adaptive immunity in Parkinson's disease.
    Harms AS; Ferreira SA; Romero-Ramos M
    Acta Neuropathol; 2021 Apr; 141(4):527-545. PubMed ID: 33555429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.